AIM
AMEXAIM ImmunoTech Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.24-0.00 (-0.17%)
01:30 PM07:45 PM
News · 26 weeks60+40%
2026-03-082026-08-30
Mix3390d
- SEC Filings19(58%)
- Other12(36%)
- Offering1(3%)
- Market1(3%)
Latest news
25 items- PRAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer. This newly issued U.S. patent expires December 20, 2039. Ampligen is a wide-spectrum Toll-like receptor 3 (TLR3) agonist, among other biological effects, and has been investigated for the treatment of various cancers, among other conditions. The Company has been issued multiple patents, and has filed multiple additional patent applications, directed to the use of
- PRAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand ConferenceVideo webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, AIM Chief Executive Officer Thomas Equels presented the Company's investment thesis, highlighting why he believes now is a pivotal time for AIM. The presentation discusses the Company's progress advancing Ampligen® through the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, including successful completion of enrollment ahead of schedule, Ampligen dosing of the final patient and the anticipated transition into primary endpoint
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- PRAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleArticle by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its potential application as a broad-spectrum prophylactic or early-onset antiviral countermeasure in Ebola and its variants Access the article here OCALA, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the publication of an article authored by AIM Chief Executive Officer Thomas K. Equels in "Breaking Defense" titled, "Biodefense is force protection: Ready today, prepared for tomorrow." The article, which includes
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 8-K filed by AIM ImmunoTech Inc.8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic CancerCompleted Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious Disease Initiatives in Ebola OCALA, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported financial results for the second quarter ended June 30, 2026, and provided a business update highlighting continued operational execution across its lead pancreatic cancer program. "AIM continues to execute a clear and disciplined strategy centere
- SECSEC Form 10-Q filed by AIM ImmunoTech Inc.10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Shareholder Director Nominations, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection PointOCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. Following planned data collection, DURIPANC Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC’s primary endpoint is Clinical Benefit Rate ("CBR"), defi
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form S-8 filed by AIM ImmunoTech Inc.S-8 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer ProgramAccess it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen® for its next stage of development. In the segment, Mr. Equels highlights the urgent unmet need facing patients with pancreatic cancer, reviews recent progress across the Company's DURIPANC Phase 2 clinical program evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab), and dis
- SECSEC Form DEF 14A filed by AIM ImmunoTech Inc.DEF 14A - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 424B3 filed by AIM ImmunoTech Inc.424B3 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesOCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company. At the center of AIM's strategy is Ampligen® (rintatolimod), the Company's proprietary TLR3 agonist immunotherapy, which is being evaluated in the ongoing Phase 2 DURIPANC study in combination with AstraZeneca's PD-L1 inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. Pancrea
- SECSEC Form EFFECT filed by AIM ImmunoTech Inc.EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesOCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. Details for the presentation are as follows: Date and Time: Wednesday, June 24, 2026 at 2:40 – 3:00 PM ETPresenter: Thomas Equels, AIM ImmunoTech’s Chief Executive Officer Registration Link: HERE About Webull Financial Webull Corporation (NASDAQ:BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 16 markets ac
- SECSEC Form 424B3 filed by AIM ImmunoTech Inc.424B3 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerOCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. With this final subject, Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC's primary endpoint is Clinical Benefit Rate ("CBR"), defined as the proportion of patients achieving stable disease, partial response or complete response
- SECSEC Form S-1 filed by AIM ImmunoTech Inc.S-1 - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form EFFECT filed by AIM ImmunoTech Inc.EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form PRE 14A filed by AIM ImmunoTech Inc.PRE 14A - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
AIM FAQ
5 questionsWhat does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides...Where does AIM stock trade?
AIM ImmunoTech Inc. (AIM) is listed on AMEX.What sector and industry is AIM in?
AIM ImmunoTech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to AIM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare AIM side-by-side with any of them on Quantisnow.How can I track AIM on Quantisnow?
Quantisnow aggregates AIM ImmunoTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIM to receive live email and push alerts on every new disclosure.